一项评价度伐利尤单抗 + Oleclumab 和度伐利尤单抗 + Monalizumab 用于根治性含铂药物同步放化疗后未进展的局部晚期（III 期）、不可切除非小细胞肺癌（NSCLC）患者的双盲、安慰剂对照、随机、多中心、国际、III 期研究（PACIFIC-9）（临床试验）
Hits:
Release time:2026-10-17 Project Number:ZL0118 -
|
 Zip Code:9a49c97c6893c744a325b48a3262d94f487045f24033622bca83ee091e2cafd653123d09609be05a20314a7a5db597a6629c78675263aeed112299ead5c57e3682f709c04d293adca0f099e5db123be18327f9e1e42033b189372f5299edaa9f1794acf7727d6c3efc7e37fd2b8859c44763a1481460d28c529794362a8a77cb Fax:12e0293f9ec0818bdb2aabe3ee6471f48d2458962000e0be4f5c3e4533527d64c2fbe89d8dae4901e3c6261c0c43ae72d467381e85e57b53b5c6c97aeae965596fb7467328a4dcbb7ce11c8947911b77e182ea144eaa186cd47896194121917600ead88e703264e654b121a3a6331abe0f5236bf41e19185f343340b93ea9ea4 Postal Address:452ef621aec68cad625b70c6b16a551ab3c2d558d6a7093cb6611d4e100e1285678ae4d65ea82ab6155050ce5334880e9f03368fe0f54caba4a78ae859f201553e8843215f9f24d9bff7a52ace83efa8bf2cbd3ffe1c09348ce625bf70cbb03f9e4380147861d2387c68e5b88f98d98641a2f2d8c7cefc311f22aad6373d6ce5 Office Phone:12e0293f9ec0818bdb2aabe3ee6471f48d2458962000e0be4f5c3e4533527d64c2fbe89d8dae4901e3c6261c0c43ae72d467381e85e57b53b5c6c97aeae965596fb7467328a4dcbb7ce11c8947911b77e182ea144eaa186cd47896194121917600ead88e703264e654b121a3a6331abe0f5236bf41e19185f343340b93ea9ea4 Email:ba35f1d2051cd924728fc7208f023bc334466045070b15fb79460fed50d6f8e35f7c5d27ccd8388c0c30f0ef776a7231cfb117ceccc4e46342cf8abe45b8e465a4f44f546e210e3917567fd9fb1815ff39ee56aecdfe938057931556be96dc99fefd6c5e0ef91b48119595a6f8a0d91041e55dc563e8f1a362823f8c65c5b57f
|
MOBILE Version